This study also challenged a long-held paradigm of type 1 and 2 cytokine antagonism by newly identifying IL-13+ IFN-γ+ CD8+ T cells that may potentially promote inflammation in SLE. This evidence concerns the gene IFNG and systemic lupus erythematosus.